Market Overview

Deutsche Bank Loves These Small-Cap Biotech Stocks

Share:
Deutsche Bank Loves These Small-Cap Biotech Stocks
Related PTCT
Credit Suisse Says PTC Therapeutics Could Trade Up Between $80 And $100
Watch These 8 Huge Call Purchases In Wednesday Trade
Related ALNY
Alnylam's Healthy Earnings Boost Price, Prompts Vetr Users To Call Hold
Benzinga's Top Upgrades, Downgrades For February 2, 2017

Deutsche Bank on Thursday named its top Small-Cap Biotech picks for 2015. The top picks were selected because they were either a disruptive technology, a rare or orphan disease market, an unmet need market or a stock with a big-time catalyst.

Here is what to watch for in Deutsche's top picks.

PTC Therapeutics, Inc. (NASDAQ: PTCT)

Deutsche highlighted PTC Therapeutics as its very top pick for 2015. PTC Therapeutics is expecting to release Phase 3 confirmatory trial data for Duchenne muscular dystrophy (DMD) in the second half of 2015.

Deutsche set a $75 price target.

Shares traded recently at $55.13, down 4.8 percent.

Related Link: The 5 Biggest Biotech Stocks

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)

Alnylam is Deutsche's favorite long-term pick. The company on Wednesday raised approximately $450 million through a public offering of about 4.7 million shares. Deutsche believes Anlylam's pipeline has broad applicability.

Deutsche set a $155 price target.

Shares traded recently at $89.24, up 2.15 percent.

Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)

Achillion is Deutsche's most underappreciated stock in early 2015. Achillion is developing ACH-3422 (a nucleotide NS5B polymerase inhibitor) for HCV and Deutsche believes Phase 1 data released last year looked encouraging.

Achillion is expecting to release full data for ACH-3442 at a medical meeting in the first half of 2015.

Deutsche set a $25 price target.

Shares traded recently at $15.30, up 2.75 percent.

Genfit (EPA: GNFT)

Deutsche selected Genfit as its top pick in the first half of 2015. Genfit's lead asset is GFT-505, which is being studied in treating NASH.

The company has an important binary Phase 2b data readout in March. Deutsche estimates a $30 billion peak global market potential for NASH and believe Genfit is a high-risk, high-reward stock in the sector.

Deutsche set a €110 price target.

Latest Ratings for PTCT

DateFirmActionFromTo
Nov 2016Credit SuisseUpgradesNeutralOutperform
Nov 2016CitigroupUpgradesNeutralBuy
Aug 2016CitigroupMaintainsNeutral

View More Analyst Ratings for PTCT
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Long Ideas Health Care Reiteration Analyst Ratings Trading Ideas Best of Benzinga

 

Related Articles (ACHN + ALNY)

View Comments and Join the Discussion!